There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on RxSight (RXST – Research Report) and Adaptive Biotechnologies (ADPT – Research Report) with bullish sentiments.
RxSight (RXST)
BTIG analyst Ryan Zimmerman maintained a Buy rating on RxSight yesterday and set a price target of $61.00. The company’s shares closed last Friday at $54.95, close to its 52-week high of $56.85.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for RxSight with a $48.88 average price target, representing a -11.1% downside. In a report issued on February 12, Stifel Nicolaus also maintained a Buy rating on the stock with a $54.00 price target.
See today’s best-performing stocks on TipRanks >>
Adaptive Biotechnologies (ADPT)
In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Adaptive Biotechnologies, with a price target of $6.00. The company’s shares closed last Friday at $3.85, close to its 52-week low of $2.61.
According to TipRanks.com, Massaro is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adaptive Biotechnologies with a $7.00 average price target, implying a 79.0% upside from current levels. In a report issued on February 15, TD Cowen also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RXST:
- RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- RxSight price target raised to $54 from $45 at Stifel
- RxSight price target raised to $41 from $35 at Needham
- RxSight up 9% in pre-market after above-consensus pre-announcement for Q4
- RxSight price target raised to $45 from $40 at Stifel
